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Objective: Perioperative stroke and death (PSD) are more common after carotid artery stenting (CAS) than after carotid
endarterectomy (CEA) in symptomatic patients, but whether this is also true in asymptomatic patients is unclear.
Furthermore, use of both CEA and CAS varies geographically, suggesting possible variation in outcomes. We compared
odds of PSD after CAS and CEA in asymptomatic patients to determine the impact of this variation.
Methods: We identiﬁed CAS and CEA procedures and hospitals where they were performed from 2005 to 2009 California
hospital discharge data. Preoperative symptom status andmedical comorbidities were determined using administrative codes.
We compared PSD rates after CAS and CEA using logistic regression and propensity score matching.We quantiﬁed hospital-
level variation in the relative utilization of CAS by calculating hospital-speciﬁc probabilities of CAS use among propensity
score-matched patients. We then calculated a weighted average for each hospital and used this as a predictor of PSD.
Results: We identiﬁed 6053 CAS and 36,524 CEA procedures that were used to treat asymptomatic patients in 278
hospitals. Perioperative stroke and death occurred in 250 CAS and 660 CEA patients, yielding unadjusted PSD rates of
4.1% and 1.8%, respectively (P < .001). Compared with CAS patients, CEA patients were more likely to be older than 70
years (66% vs 62%; P < .001) but less likely to have three or more Elixhauser comorbidities (37% vs 39%; P < .001).
Multivariate models demonstrated that CAS was associated with increased odds of PSD (odds ratio [OR], 1.865; 95%
conﬁdence interval [CI], 1.373-2.534; P < .001). Estimation of average treatment effects based on propensity scores also
demonstrated 1.9% increased probability of PSD with CAS (P < .001). The average probability of receiving CAS across all
hospitals and strata was 13.8%, but the interquartile range was 0.9% to 21.5%, suggesting signiﬁcant hospital-level
variation. In univariate analysis, patients treated at hospitals with higher CAS utilization had higher odds of PSD
compared with patients in hospitals that performed CAS less (OR, 2.141; 95% CI, 1.328-3.454; P[ .002). Multivariate
analysis did not demonstrate this effect but again demonstrated higher odds of PSD after CAS (OR, 1.963; 95% CI,
1.393-2.765; P < .001).
Conclusions: Carotid endarterectomy has lower odds of PSD compared with CAS in asymptomatic patients. Increased
utilization of CAS at the hospital level is associated with increased odds of PSD among asymptomatic patients, but this
effect appears to be related to generally worse outcomes after CAS compared with CEA. (J Vasc Surg 2013;57:627-34.)Severe carotid artery stenosis is related to stroke, and
carotid endarterectomy (CEA) is efﬁcacious in both
secondary1,2 and primary3,4 stroke prevention compared
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://dx.doi.org/10.1016/j.jvs.2012.09.036is a newer modality for stroke prevention, but randomized
controlled trials (RCTs) have not consistently shown
equivalence between CAS and CEA.5-10 Some authors
have argued that for certain high-risk patients, CAS is
equivalent to CEA,6 but multiple RCTs have demonstrated
that CAS has higher perioperative stroke and death (PSD)
rates in symptomatic patients.7-9 In asymptomatic patients,
the comparison between CEA and CAS is less clear, with
RCTs failing to ﬁnd a signiﬁcant difference in this
subgroup.6,10 Some observational studies have not found
a difference between CAS and CEA,11,12 whereas others
show CEA to be superior.13,14 Meanwhile, others have
emphasized the use of best medical therapy alone for
asymptomatic patients who cannot undergo CEA safely,15
and some have suggested that all asymptomatic patients
should be treated with only best medical therapy and
undergo neither CEA nor CAS.16 Despite these contradic-
tory ﬁndings, use of CAS is expanding, apparently at the
expense of CEA.17 In addition, there is wide variability in
the use of both carotid revascularization (CR) techniques627
Table I. Deﬁnition of hemispheric cerebral ischemia




362.30 Retinal vascular occlusion, unspeciﬁed
362.31 Central retinal artery occlusion
362.32 Retinal arterial branch occlusion
362.33 Partial retinal arterial occlusion, Hollenhorst
plaque, retinal microembolism
362.34 Transient retinal arterial occlusion, amaurosis
fugax
362.84 Retinal ischemia
433.11 Occlusion and stenosis of carotid artery with
cerebral infarction
433.31 Occlusion and stenosis of multiple and bilateral
arteries with cerebral infarction
434.01 Occlusion of cerebral arteries (cerebral
thrombosis) with cerebral infarction
434.11 Cerebral embolism with cerebral infarction
434.91 Cerebral artery occlusion, unspeciﬁed, with
cerebral infarction
435.8 Other speciﬁed transient cerebral ischemia
435.9 Unspeciﬁed transient cerebral ischemia:
impending cerebrovascular accident;
intermittent cerebral ischemia; transient
ischemic attack
ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation.
Fig 1. Selection of hospital discharge records for analysis. CAS,
Carotid artery stenting; CEA, carotid endarterectomy; CR, carotid
revascularization; OSHPD, California Ofﬁce for Statewide Health
Planning and Development.
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ation in physician or hospital “enthusiasm” for CAS to be
a key driver for this variability,17 but the clinical effect of
this variation is not clear, as variation by itself does not
address the issue of appropriateness.19 We have two aims
for our study. First, we sought to compare patient- and
hospital-level PSD outcomes after CAS vs CEA in an
administrative database to compare the rate of periopera-
tive events after the two procedures. Second, we sought
to determine if variation in relative hospital utilization of
CAS is linked to PSD in asymptomatic patients after
any CR.
METHODS
Data source. After obtaining Institutional Review
Board approval from the University of Pittsburgh, we
obtained de-identiﬁed patient discharge data from the
California Ofﬁce for Statewide Health Planning and
Development (OSHPD) for the years 2005 through 2009.
The state of California is the most populous state in the
United States and, as such, provides a convenient and
economical single data source to obtain administrative
data.
All patients discharged from a hospital in California,
excluding federally funded hospitals such as Veterans
Affairs or military hospitals, are entered into an OSHPD
database. Due to the de-identiﬁcation process, variables
are sometimes masked in order to ensure anonymity. Inter-
national Classiﬁcation of Diseases, Ninth Revision, ClinicalModiﬁcation (ICD-9-CM) procedure and diagnosis codes
are included with each record along with a “present on
admission” (POA) ﬂag that we used to discriminate neuro-
logically symptomatic from asymptomatic patients and to
deﬁne PSD.11 We ﬁrst identiﬁed patients who underwent
CR, as deﬁned by ICD-9-CM procedure codes 38.12
and 00.63. We then assessed if the admitting or diagnosis
codes, in any position, were associated with hemispheric
cerebral ischemia or ophthalmic artery occlusion or embo-
lism (Table I). If the codes were POA, the patient was
identiﬁed as being symptomatic. Patients without such
codes, or those in whom the codes were not POA, were
deﬁned as being asymptomatic. For this study, PSD was
deﬁned as the combined end point of death being the
discharge disposition of the hospitalization or the presence
of ICD-9 codes that suggested stroke, hemiplegia, or other
manifestations of cerebral infarction that were not POA.11
The ICD-9 codes have demonstrated good speciﬁcity and
positive predictive value for cardiovascular risk factors.20 In
addition, every discharge is associated with a unique
hospital code, which facilitates analysis at the hospital level.
Patient population. Using ICD-9-CM codes, we
identiﬁed CAS and CEA procedures and hospitals where
they were performed, along with preoperative symptom
status. The ICD-9-CM codes also provided evidence for
patient comorbidities, which were then identiﬁed using the
method of Elixhauser.21 Records from pediatric patients
and prisoners were excluded, in accordance with our
submission to our local Institutional Review Board.
Statistical analysis. We tested two null hypotheses:
(1) PSD are equally common after CEA and CAS among
asymptomatic patients, adjusting for observable patient
characteristics; and (2) PSD after CR (both CEA and
CAS) are unaffected by a hospital’s relative utilization of
CAS, adjusting for observable patient and hospital
characteristics.
Fig 2. Annual asymptomatic carotid revascularization procedures
in California. CAS, Carotid artery stenting; CEA, carotid
endarterectomy.
Table II. Selected demographics of all unmasked
asymptomatic patient records
Variable CEA CAS P value
Total records 26,841 3476
Male 57% 56% .509
White race 90% 83% <.001
Hispanic ethnicity 8% 9% .014
Age >70 years 66% 62% <.001
No. of Elixhauser comorbidities 2.24 2.29 .019
$3 Elixhauser comorbidities 37% 39% <.001
Congestive heart failure 8% 11% <.001
Chronic pulmonary disease 20% 17% <.001
Complicated diabetes mellitus 5% 4% .103
Renal failure 9% 10% .004
Obesity 8% 5% <.001
Hypertension, complicated 10% 11% .016
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Unmasked patients were used in all multivariate regression analyses.
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obtained using logistic regression on all available records
of asymptomatic patients. Multiple models were generated,
including single-level models that assumed independence
of the observations and multilevel models with random
intercepts for each hospital that accounted for the nesting
of observations within hospitals. Covariates were chosen
using backward elimination for dichotomous variables
and Akaike information criterion, Bayesian information
criterion, and the likelihood ratio test to determine the
importance of the year that the procedure was performed.
Patient age was retained to maintain clinical validity of the
models. We also utilized a propensity score matching tech-
nique to examine the average causal treatment effect of
CAS treatment. The propensity score is the probability of
receiving CAS, as opposed to CEA, for a patient with
speciﬁc prognostic factors that are available in the database.
We computed the propensity score by using a probit
model, with the dependent model being the receipt of
CAS and the independent variables being patient age,
gender, ethnic background, and Elixhauser variables.
Patients were then grouped into strata of similar propensity
score with upper and lower limits constructed to ensure
that covariates were similarly distributed and the average
propensity score was approximately equal for CEA and
CAS patients within strata. Finally, we used stratiﬁcation
matching, in which outcomes after CEA and CAS were
compared within each stratum and then averaged across
all strata, in order to identify the effect of CAS on PSD.22
We investigated the effect of the relative level of
hospital utilization of CAS on PSD. We reasoned that
the proportion of patients at a hospital who underwent
CAS, as opposed to CEA, could serve as a quantitative
measure of a hospital’s preference for CAS. We used the
strata from the propensity scores deﬁned earlier and calcu-
lated the proportion that underwent CAS for each hospitalwithin each stratum. Within strata, patients are similar
based on observed characteristics, and, if all hospitals
treated such patients comparably, each hospital would
have similar proportions that underwent CAS. Therefore,
differences between hospitals can be thought of as a form
of geographic variation. We then calculated a weighted
average across all strata for the hospital. This weighted
average served as a measure of relative CAS utilization for
the hospital.
We considered using the unadjusted proportion of
CAS procedures as our metric for utilization, but this
would unduly penalize hospitals that treated patients with
more comorbidities, as those patients appeared more likely
to be treated with CAS and independently also suffer PSD.
We repeated logistic regression to estimate the associa-
tion of different levels of relative CAS utilization on PSD
using multilevel logistic regression models with random
slopes and intercepts for each hospital. Building on our
previous models, we included hospital-level variables
including the relative utilization metric, CAS and CEA
volume, and number of patient discharges. Interaction
terms between hospital-level CAS utilization and CAS
were also evaluated.
Data and statistical analysis were performed with
StataMP (version 11.2; StataCorp LP, College Station,
Tex).
RESULTS
Patient characteristics. During the analysis period
from 2005 to 2009, a total of 47,598 discharge records
were identiﬁed that recorded CEA or CAS. We removed
records of patients who were younger than 18 years, pris-
oners, or those who underwent both CEA and CAS during
their hospitalization (195 records removed). We then
focused on asymptomatic patients only (4826 records
removed), yielding an analytic ﬁle of 42,577 CR records:
6053 CAS and 36,524 CEA (Fig 1). In this group, the
number of annual CEA was at its highest in 2005 and
Table III. Regression coefﬁcients for multilevel model predicting perioperative stroke and death using demographic and
clinical variables
Variable OR SE 95% CI P value
CAS (CEA as baseline) 1.865 0.292 1.373-2.534 <.001
White race (nonwhite as baseline) 0.864 0.117 0.662-1.127 .281
Hispanic ethnicity (non-Hispanic as baseline) 1.485 0.209 1.127-1.958 .005
Male gender (female as baseline) 0.824 0.071 0.696-0.976 .025
Age demographics (age 70-74 years as baseline)a
<50 years 1.514 0.516 0.776-2.952 .224
50-54 years 1.125 0.330 0.634-1.998 .687
55-59 years 1.178 0.262 0.761-1.822 .463
60-64 years 1.436 0.241 1.034-1.996 .031
70-74 years 1.005 0.163 0.730-1.382 .977
75-79 years 1.191 0.171 0.900-1.578 .222
80-84 years 1.233 0.184 0.920-1.653 .160
$85 years 1.634 0.265 1.189-2.246 .002
Elixhauser comorbidities
Congestive heart failure 1.941 0.267 1.483-2.541 <.001
Peripheral vascular disorders 1.333 0.141 1.083-1.640 .007
Paralysis 6.937 1.661 4.339-11.09 <.001
Other neurologic disorders 2.450 0.424 1.746-3.438 <.001
Metastatic cancer 2.288 1.056 0.926-5.655 .073
Solid tumor without metastases 1.887 0.519 1.101-3.236 .021
Weight loss 3.542 1.097 1.930-6.500 <.001
Fluid and electrolyte disorders 1.469 0.282 1.008-2.142 .045
$3 Elixhauser comorbidities 1.030 0.036 0.961-1.104 .401
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; OR, odds ratio; SE, standard error.
aOverall P ¼ .0879.
Table IV. Number of CEA and CAS procedures and
associated PSD by year
Year 2005 2006 2007 2008 2009
Count of CAS 1190 1548 1117 1100 1098
CAS PSD count 42 50 48 44 66
CAS PSD rate 3.5% 3.2% 4.3% 4.0% 6.0%
Count of CEA 7598 7197 7267 7225 6577
CEA PSD count 153 117 124 145 121
CEA PSD rate 2.0% 1.6% 1.7% 2.0% 1.8%
CAS, Carotid artery stenting; CEA, carotid endarterectomy; PSD, peri-
operative stroke and death.











1 56 1253 4.4% 5.0% 5.3% 4.9%
2 545 6262 7.8% 8.7% 8.8% 8.3%
3 1095 9601 10.0% 10.2% 10.5% 10.2%
4 432 3269 11.1% 12.0% 12.3% 11.8%
5 393 2457 12.9% 12.9% 13.2% 13.0%
6 123 527 14.4% 14.9% 15.3% 14.9%
7 421 1940 16.7% 17.6% 18.2% 17.4%
8 323 1288 19.9% 21.3% 22.0% 21.0%
9 87 243 26.9% 29.0% 32.7% 30.1%
10 1 1 50.8% 52.7% 54.7% 52.7%
Total 3476 26,841
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Strata were constructed to ensure that covariates were similarly distributed
and the average propensity score was approximately equal between the CEA
and CAS patients.
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reduction of 16% by 2009. Meanwhile, there was little
net change in the number of annual CAS between 2005
and 2009 (Fig 2). Compared with CAS patients, CEA
patients were more likely to be older than 70 years (62% vs
66%; P < .001) but were less likely to have three or more
Elixhauser comorbidities (37% vs 39%; P < .001) or to
carry a diagnosis of congestive heart failure (11.5% vs 7.5%;
P < .001). Selected demographics and comorbidities are
listed in Table II for patients with unmasked data. Of note,
multivariate regression models used only patients with
unmasked data (30,317 CR records: 3476 CAS and
26,841 CEA).
Association of CAS with PSD. Perioperative stroke
and death occurred after 250 CAS and 660 CEA, yielding
unadjusted PSD rates of 4.1% and 1.8%, respectively(P < .001), which corresponds to univariate logistic regres-
sion that also estimated a higher odds of PSD among
asymptomatic patients with CAS (odd ratio [OR], 2.341;
95% conﬁdence interval [CI], 2.019-2.715; P < .001).
In a single-level logistic regression that adjusted for demo-
graphics, including race, age, and gender, and clinical
characteristics, as deﬁned by Elixhauser comorbidities, CAS
was still signiﬁcantly associated with PSD (OR, 1.948; 95%
CI, 1.583-2.398; P < .001). The effect of CAS remained
Table VI. Selected demographics of patients in
propensity score stratum 3
Variable CAS CEA
Total records 1095 9601
Male 60% 61%
White race 99% 99%
Hispanic ethnicity 3% 4%
Age >70 years 77% 78%
No. of Elixhauser comorbidities 1.78 1.77
$3 Elixhauser comorbidities 24% 23%
Congestive heart failure 1% 1%
Chronic pulmonary disease 5% 6%
Complicated diabetes mellitus 2% 3%
Renal failure 7% 7%
Obesity 2% 1%
Hypertension, complicated 8% 7%
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Fig 3. Histogram of weighted average hospital-level probability of
performing carotid artery stenting (CAS) vs carotid endarterec-
tomy (CEA) across all propensity score-matched strata (“relative
CAS utilization”).
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covariates (OR, 1.960; 95% CI, 1.595-2.409; P < .001).
Nested models with random intercepts and random coef-
ﬁcients that account for the relationship of patients within
hospitals also demonstrate increased odds of PSD associ-
ated with CAS (OR, 1.865; 95% CI, 1.373-2.534; P <
.001). Regression coefﬁcients for the ﬁnal nested model are
presented in Table III.
Death occurred after 181 CEA and 86 CAS, yielding
raw death rates of 0.5% and 1.4%, respectively (P < .001).
Perioperative stroke occurred after 550 CEA and 191
CAS, for rates of 1.5% and 3.2%, respectively (P < .001).
We also investigated the impact of year on PSD rates.
In univariate analysis, CAS PSD rates appeared to increase
from 3.5% in 2005 to 6.0% in 2009 (P ¼ .002), whereas
CEA PSD rates fell from 2.0% to 1.8% for the same time
period (P ¼ NS) using a two-sample test of proportions
(Table IV). However, in multivariate analysis, the year of
procedure did not improve model ﬁt and was not included
in the ﬁnal model.
Propensity score matching results. Blocks of propen-
sity score-matched patients were generated in order to
balance the demographics variables and Elixhauser
comorbidities that were used as covariates. Ten blocks were
created (Table V). As designed, patients within blocks were
better balanced on their demographic and observed clinical
characteristics than in the original population, as illustrated
for block 3 (Table VI). Estimates of the average effect of
CAS using stratiﬁcation matching again demonstrated that
CAS was inferior to CEA. Patients treated with CAS had
a 1.9% higher probability of PSD than did patients treated
with CEA (P < .001).
Hospital CAS utilization analysis results. A total of
278 hospitals that performed at least one CEA or CAS
from 2005 to 2009 were identiﬁed; of these, ﬁve did not
have a utilization metric calculated due to a combination
of very low volumes and missing demographic information,
leaving 273 hospitals. Our metric for hospital-level relative
utilization of CAS, which is the average probability of per-
forming CAS vs CEA across all propensity score-matchedstrata, weighted by the number of procedures in each
stratum, had an average value of 13.8%, median value of
5.2%, and interquartile range of 0.9% to 21.5% (Fig 3).Most
hospitals that perform CR concentrate on CEA, with CAS
being limited to a few centers. Univariate logistic regression
demonstrated statistically signiﬁcant increased odds of PSD
with increasing hospital-level utilization (OR, 2.141; 95%
CI, 1.328-3.454; P¼ .002). Multivariate regression analysis
was also performed, controlling for patient characteristics
associated with PSD from the previous models. We also
controlled for hospital-level characteristics, including CEA
and CAS volume, total number of hospital discharges, and
accounting for the clustering of observations within hospi-
tals. The effect of hospital-level utilization on PSD became
nonsigniﬁcant (OR, 1.407; 95% CI, 0.497-3.980; P ¼
.520), whereas the effect of CAShad approximately the same
magnitude as in previous models (OR, 1.963; 95% CI,
1.393-2.765; P < .001).
In the ﬁnal model, we failed to ﬁnd evidence for
a volume-outcome relationship at the hospital level for
either CEA (OR, 0.974 for an increase in 100 CEA proce-
dures; 95% CI, 0.900-1.053; P ¼ .502) or CAS (OR,
0.805 for an increase in 100 CAS procedures; 95% CI,
0.615-1.054; P ¼ .114). The interaction term between
our metric for hospital utilization and use of CAS also
was not signiﬁcant (P ¼ .581) and was dropped from the
ﬁnal model. Regression coefﬁcients for the ﬁnal model
are given in Table VII.DISCUSSION
We have three principal ﬁndings. First, among the
asymptomatic patients we identiﬁed, we found a PSD
rate of 4.1% after CAS and 1.8% after CEA. Current guide-
lines for CEA in asymptomatic patients call for a
PSD rate <3% in patients with asymptomatic carotid
disease.15,23,24 CEA in our administrative dataset meets
this standard, whereas CAS does not. Second, after
Table VII. Regression coefﬁcients for multilevel model predicting perioperative stroke and death using demographic,
clinical, and hospital variables
OR SE 95% CI P value
Hospital-level variables
Weighted average probability of performing CAS across all propensity
score-matched strata (utilization of CAS)
1.407 0.746 0.497-3.98 .520
No. of CAS procedures performeda 0.805 0.110 0.615-1.054 .114
No. of CEA procedures performeda 0.974 0.039 0.900-1.053 .502
No. of patient dischargesb 1.011 0.015 0.982-1.040 .465
Patient-level variables
CAS (CEA as baseline) 1.963 0.343 1.393-2.765 <.001
White race (nonwhite as baseline) 0.881 0.121 0.674-1.152 .355
Hispanic ethnicity (non-Hispanic as baseline) 1.453 0.205 1.102-1.916 .008
Male gender (female as baseline) 0.825 0.071 0.696-0.977 .025
Age demographics (age 70-74 years as baseline)
<50 years 1.498 0.511 0.768-2.922 .236
50-54 years 1.120 0.328 0.631-1.988 .699
55-59 years 1.169 0.260 0.756-1.809 .483
60-64 years 1.429 0.240 1.028-1.985 .034
65-69 years 1.006 0.164 0.731-1.384 .970
75-79 years 1.194 0.171 0.901-1.581 .216
80-84 years 1.237 0.185 0.923-1.658 .154
$85 years 1.641 0.266 1.194-2.255 .002
Elixhauser comorbidities
Congestive heart failure 1.936 0.267 1.48-2.534 <.001
Peripheral vascular disorders 1.334 0.141 1.084-1.642 .006
Paralysis 6.934 1.661 4.342-11.073 <.001
Other neurologic disorders 2.451 0.424 1.747-3.439 <.001
Metastatic cancer 2.320 1.056 0.940-5.727 .068
Solid tumor without metastases 1.885 0.519 1.100-3.231 .021
Weight loss 3.456 1.097 1.884-6.339 <.001
Fluid and electrolyte disorders 1.462 0.282 1.003-2.13 .048
$3 Elixhauser comorbidities 1.029 0.036 0.96-1.102 .424
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; OR, odds ratio; SE, standard error.
aPer 100 procedures.
bPer 10,000 discharges.
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CAS with multivariate logistic regression techniques, we
still found that CAS was associated with approximately
twice the odds of PSD compared with CEA. We supple-
mented this analysis with a propensity score matching tech-
nique to minimize the risk of confounding based on
observed data and again found a statistically signiﬁcant
increased probability of PSD with CAS. Third, we found
a univariate relationship between hospital-level utilization
of CAS and PSD, with increased relative utilization of
CAS associated with increased PSD among asymptomatic
patients undergoing CR; this relationship is not signiﬁcant
in multivariate analysis.
Our ﬁrst two ﬁndings regarding the higher PSD rate
for CAS compared with CEA have been reported previ-
ously by other investigators using different datasets and
statistical methodologies.13,14 In addition, the absolute
PSD rate after CEA of 1.8% for all asymptomatic patients
is in line with the approximately 1.4% PSD rate in both
observational25 and a recent contemporary RCT.10 Given
the all-inclusive nature of the OSHPD data, these rates
likely reﬂect the true CEA PSD rates in the community
in the time period of interest and the real world effective-
ness of CEA. Meanwhile, the observed PSD rate for CASwas 4.1%, which certainly is above the 3% upper limit
prescribed for CEA and above the guidelines set by prom-
inent insurance groups for management of asymptomatic
carotid disease.26 Although such a rate may be acceptable
for symptomatic patients, it is important to recognize
that our analysis was restricted to asymptomatic patients
in whom initial perioperative risk of stroke must be
balanced against the modest stroke prevention beneﬁt
that operating on an asymptomatic patient implies.16 By
itself, this is noteworthy and consistent with recent Society
for Vascular Surgery guidelines suggesting that CAS should
not be offered to asymptomatic patients.15 The higher
odds of PSD persists after adjustment for the slightly
higher, and clinically small, burden of medical comorbid-
ities of patients who were treated with CAS at the time,
as described by other investigators.13,14
Our third ﬁnding is the most novel; the difference in
outcomes in CEA and CAS drives differences in overall
CR outcomes. Other published reports have detailed
geographic variation in the use of CAS vs CEA17,18 and
have linked some of this variation to physician specialty,27
but they have yet to describe a clinical effect from this vari-
ation. To our knowledge, we are the ﬁrst to suggest that
increased hospital-level utilization of CAS is associated
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multivariate analysis, the effect of variation in hospital-
level utilization is diminished, suggesting that the hospital’s
utilization level does not affect the likelihood of the PSD
outcome; rather, it is the generally worse outcomes after
CAS that account for the effect seen in univariate analysis.
Beyond the choice of CAS vs CEA, our ﬁndings must
be interpreted in light of recent studies suggesting that for
many asymptomatic patients, especially those with short life
expectancies, best medical therapy may be the optimal
treatment modality.15,16 Approximately 90% of patients
who underwent CR in this analysis appeared to be asymp-
tomatic. Furthermore, current Society for Vascular Surgery
guidelines emphasize the importance of a minimum life
expectancy of at least 3 years in order for there to be
a beneﬁt in asymptomatic patients undergoing CEA.15
We look forward to future RCTs that may address the
choice of CEA, CAS, and best medical therapy in asymp-
tomatic patients.28
As with other observational studies using administra-
tive databases, our analysis rests on the accuracy of the
diagnosis codes, and signiﬁcantly different coding of
comorbidities or complications after CEA or CAS could
affect our analysis. Furthermore, residual confounding
may still be present, despite our efforts. Clinically impor-
tant variables such as degree of stenosis, anatomy, or
surgical history were not available to us and could not be
included in our models. Similarly, our ability to distinguish
symptomatic from asymptomatic patients is limited by the
nature of administrative data. Finally, due to the structure
of the database, longitudinal patient identiﬁers are not
available, so only outcomes related to the initial hospital
stay can be analyzed.
CONCLUSIONS
In this analysis of a recent administrative database, odds
of PSD after CAS are twice as high as odds of PSD after
CEA. Furthermore, hospital-level utilization of CAS is asso-
ciated with PSD, but this effect appears to be fully explained
by generally worse outcomes after CAS compared with
CEA. These results support recent guidelines suggesting
that in asymptomatic patients with appropriate anatomy
and lesion characteristics, CEA should be the ﬁrst-line
therapy with best medical therapy offered to patients who
are poor surgical risks or have short life expectancies. The
role of CAS in this patient population needs further study
before it can be recommended for broader use.
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